Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Business Wire•10/08/2026•16:00 ET
0
Whiz Insights
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns observed
Get started
Create a free account to read the full story.